Sellside advisors Jefferies and JP Morgan are considering offering staple financing for a potential sale of French drug delivery specialist Nemera, according to 9fin sources.
The banks are working with sponsors Astorg and Montagu on the sale of their portfolio company.
The staple financing could result in a syndicated loan solution for the buyout, but sources said the next owner of Nemera could still find a private credit debt package better suited for the company’s growth plan. Nemera’s existing debt package is a portable unitranche.
Sources expect sponsors to launch the sale in January 2027, 9fin previously reported. Advisors will likely market Nemera off EBITDA of between €185m and €200m, depending on adjustments.
In 2025, La Caisse, GIC, Goldman Sachs and Permira led a refinancing of Nemera’s existing €770m term loan B via a unitranche, 9fin previously reported.
Nemera will attract significant interest from sponsors, partially thanks to its international footprint, as reported. It could potentially fetch a valuation of €3bn, Bloomberg reported in August.
Montagu first invested in the business in 2014, carving out the asset from UK-based Rexam, according to a press release. The sponsor then sold a stake to Astorg in 2018 while re-investing in the business. In 2025, LGT Capital Partners acquired a minority stake in Nemera.
The healthcare company produces a range of medical devices, including inhalers, insulin pens, eye droppers and pumps, according to its website.
Astorg, LGT, Jefferies, JP Morgan, Montagu and Nemera declined to comment.






